445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis

Background

Recently, systemic therapy using immune checkpoint inhibitors (ICIs) has become prevalent for treatment of patients with various types of advanced cancer; however, it remains difficult to predict prognostic outcomes in patients receiving ICIs due to heterogenous response to these agents. The objective of this study was to develop a prognostic model for advanced cancer patients treated with ICIs.

Methods

This research is approved by the Institutional Review Board of Hamamatsu University School of Medicine (No. 21-288). This study retrospectively analyzed impacts of clinical parameters on overall survival (OS) in 329 patients with several advanced solid malignant tumors who received systemic therapy using ICIs.

Results

Primary tumors of the 329 patients were as follows: lung (n=89), kidney (n=70), urinary tract (n=52), skin (n=50), stomach (n=30), esophagus (n=21) and head and neck (n=17). The median OS after the introduction of ICIs in these patients were 17.3 months. Of factors significantly associated with OS by univariate analysis, body mass index, C-reactive protein, hemoglobin, lymphocyte and platelet were identified as independent predictors of OS by multivariate analysis. When patients were classified into 3 groups based on the positive numbers of these 5 independent factors, median OSs were not reached in the favorable risk group with 0 or 1 risk factor (n=76), 19.5 months in the intermediate-risk group with 2 or 3 risk factors (n=182) and 8 months in the poor risk group (n=71) with 4 or 5 risk factors.

Conclusions

Despite being simple and objective, this model could be used as a reliable tool for prognostic prediction of advanced cancer patients receiving ICIs across multiple tumor types.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

This research is approved by the Institutional Review Board of Hamamatsu University School of Medicine (No. 21-288).

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.